Immunovant (IMVT) Total Liabilities (2018 - 2026)

Immunovant has reported Total Liabilities for 9 years, with the latest figure at $104.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 51.83% year-over-year to $104.4 million; the trailing twelve-month figure through Mar 2026 stood at $104.4 million (up 51.83% YoY), and the FY2026 full-year result was $104.4 million, up 51.83% from the prior year.
• Total Liabilities for Q1 2026 stood at $104.4 million, up from $66.3 million in the prior quarter.
• The five-year high for Total Liabilities was $104.4 million in Q1 2026, with the low at $22.2 million in Q2 2022.
• Historically, Total Liabilities has averaged $52.5 million across 5 years, with a median of $48.6 million in 2024.
• The largest YoY upside for Total Liabilities was 131.72% in 2023 against a maximum downside of 22.77% in 2023.
• Immunovant's Total Liabilities stood at $41.6 million in 2022, then declined by 22.77% to $32.1 million in 2023, then soared by 112.81% to $68.3 million in 2024, then fell by 3.01% to $66.3 million in 2025, then soared by 57.6% to $104.4 million in 2026.
• The last three Total Liabilities figures came in at $104.4 million (Q1 2026), $66.3 million (Q4 2025), and $63.3 million (Q3 2025), per Business Quant data.